Your SlideShare is downloading. ×
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Research and Innovation in Cardiovascular Diseases: The EU perspectives

1,741

Published on

Innovación y Calidad en el Sistema Nacional de Salud …

Innovación y Calidad en el Sistema Nacional de Salud
Miércoles, 25 de Junio de 2014 17:00h
http://debateSEC.secardiologia.es

Research and Innovation in Cardiovascular Diseases: The EU perspectives
Dr. Karim Berkouk
Deputy Head of Unit. DG Innovation and Research-European Commission

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,741
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Research and Innovation Dr Karim Berkouk Deputy Head of Unit for Medical Research and Ageing Health Directorate Research & Innovation DG European Commission Madrid, 25 June2014 Research and Innovation in Cardiovascular Diseases - The EU perspectives
  • 2. Research and Innovation Content Challenges in CVD Research in CVD at EU level CVD in FP7 Horizon 2020
  • 3. Research and Innovation • Ageing population • Increased disease burden: chronic diseases • Health & care sector unsustainable: under pressure to reform • Health industry under pressure for innovative solution Health main challenges
  • 4. Research and Innovation • First cause of death in Europe • Costs : 200 Billion per year • Elderly population • Co-morbidities (diabetes and obesity) • Limited innovation in recent years • Stratification of patients to predict successful treatment CVD main challenges
  • 5. Research and Innovation EU Health R&I Collaborative Research Bottom-up: ERC, MC Public- Private Partnerships IMI Bio-Eco Capacity Building Infrastructures (CT, biobank) Legislation Directives, Regulations International co-operation Global consortia GACD MS Coordination ERA-NET, JPs EDCTP EIP AHA Joint Action The EU means
  • 6. Research and Innovation FP 7 - Health - State of Play Key figures 5,5 B€ invested 1054 projects 12 505 participations 3 615 organisations 123 countries First outcomes (on 349 closed projects) 11 879 publications 3,2 average SJR* publication 227 patent applications 31 spin-offs created * SCImago Journal Ranking
  • 7. Research and Innovation FP 7 - CVD - State of Play Key figures 810 M€ invested 371 projects 1,788 participations 907 organisations 61 countries First outcomes (on 22 closed Health projects) 1,165 publications 2,5 (7,1) average SJR* publication 27 patent applications * SCImago Journal Ranking
  • 8. Research and Innovation Collabora- tive projects - €620M 77% Frontier – €113M 14% Training – €74M 9% EU CVD research – what’s being funded • translational research  atherosclerosis  arrhythmias  heart failure  cardiomyopathies  hypertension  congenital disease  stroke  biomarkers, drug target discovery and validation  tissue regeneration  imaging • comparative effectiveness research • investigator-driven trials • public health Number of projects: 71 Total Costs : € 1,041 million EU Contribution : € 907million* *data cover 2007-2013
  • 9. Research and Innovation FP 7 – CVD MS Regions funding In million € (m€) 0 0 - 0,5 0,5 - 1 1 - 0 0 - 1 1 - 3 3 - 30 30 - 32 32 - 37 37 + B N
  • 10. Research and Innovation FP 7 – CVD Spanish Regions funding ES11 ES12 ES13 ES21 ES22 ES23 ES24 ES30 ES41 ES42ES43 ES51 ES52 ES61 ES62 SPAIN key figures EC Contribution : 49.878.105 Total Costs : 65.817.228 Number of projects : 79 Number of participations : 141 Number of organisations : 81 Average amount by participations : 353.745
  • 11. Research and Innovation Average EC contribution in CVD projects 682.991 636.870 603.910 532.153 503.037 499.993 484.876 483.157 477.375 425.592 417.189 399.831 369.400 368.340 353.745 349.414 339.891 332.963 265.484 257.132 236.327 234.854 227.135 217.468 215.038 213.240 191.590 190.921 190.907 189.136 167.998 152.486 104.899 100.383 0 0 0 382.185 Netherl… Finland Sweden Israel Germany Switzer… Belgium France United… Turkey Iceland Denmark Greece Ireland Spain Italy Austria Norway Serbia Portugal Luxemb… Bulgaria Lithuania Hungary Czech… Moldov… Latvia Poland Romania Slovakia Cyprus Estonia Slovenia Croatia Malta
  • 12. Research and Innovation FP 7 – CVD connections with Spain 259 240 198 136 129 108 95 53 53 40 32 32 31 30 28 26 15 15 12 10 10 9 9 8 8 8 7 7 6 6 DE-ES ES-UK ES-IT ES-ES ES-NL ES-FR BE-ES ES-SE ES-FI CH-ES EL-ES AT-ES ES-NO ES-PT DK-ES ES-IE ES-IL ES-PL ES-RS ES-SI ES-TR ES-US ES-HU CN-ES AR-ES EE-ES ES-HR CZ-ES ES-SK ES-NZ
  • 13. Research and Innovation Horizon 2020 Perspectives
  • 14. Research and Innovation The Multiannual Financial Framework 2014-2020: European Council conclusions, 8 February 2013 • Key challenge: stabilise the financial and economic system while taking measures to create economic opportunities 1. Smart & inclusive growth (€451 billion) 2. Sustainable growth, natural resources (€373 billion) 3. Security and citizenship (€16 billion) 4. Global Europe (€58 billion) 5. Administration (€61.6 billion) Education, Youth, Sport Connecting Europe Cohesion Competitive Business SMEs HORIZON 2020 TOTAL €960 billion
  • 15. Research and Innovation What Horizon is 2020 about − Responding to the economic crisis to invest in future jobs and growth − Addressing people’s concerns about their livelihoods, safety and environment − Strengthening the EU’s global position in research, innovation and technology http://ec.europa.eu/research/horizon2020 The EU’s 2014-20 programme for research & innovation A core part of Europe 2020, Innovation Union & European Research Area
  • 16. Research and Innovation Three priorities •Excellent science •Industrial leadership •Societal challenges • European Research Council • Future and Emerging Technologies • Marie Skłodowska-Curie actions • Research infrastructures • Leadership in enabling and industrial technologies • Access to risk finance • Innovation in SMEs • Health, demographic change and wellbeing • Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the Bioeconomy • Secure, clean and efficient energy • Smart, green and integrated transport • Climate action, environment, resource efficiency and raw materials • Inclusive, innovative and reflective societies • Secure societies • Science with and for society • Spreading excellence and widening participation
  • 17. Research and Innovation Innovation Investment Package €22 billion Innovation Investment Package Joint Technology Initiatives (under Article 187) • Innovative Medicines Initiative 2 • Clean Sky (Aeronautics) 2 • Fuel Cell and Hydrogen 2 • Bio-based Industries • Electronic components and systems Joint programmes (under Article 185) • European and Developing Countries Clinical Trials Partnership (EDCTP) 2 • European Metrology Research Programme 2 • Eurostars (for SMEs) 2 • Active and Assisted Living 2
  • 18. Research and Innovation General opening • Horizon 2020 is open to participation from across the world • Automatic funding: • Member States (including overseas departments and overseas territories) • Associated Countries • exhaustive list of countries in annex to work programme (but: no longer BRIC + Mexico in this list!) • Participants from other countries only funded in exceptional cases: • when provision is made in the call text • bilateral agreement (e.g. Health challenge – NIH) • when the Commission deems it essential (case by case assessment)
  • 19. Research and Innovation International K.O. Mouse Consortium International Human Microbiome Consortium International Human Epigenome Consortium International Rare Diseases Research Consortium International Initiative for Traumatic Brain Injury Research ©rtguest/Fotolia.com Global Alliance for Chronic Diseases New! Global Research Collaboration for Infectious Disease Preparedness International Cancer Genomics Consortium Continued and growing international cooperation
  • 20. Research and Innovation Less prescriptive topic texts Two-year work programme Stronger focus on end users Broad topics Challenge-driven Health, Demographic change and wellbeing - aim Funding: € 7.5 Billion
  • 21. Research and Innovation Advancing active and healthy ageing Integrated, sustainable, citizen-centred care Improving health information, data exploitation and providing an evidence base for health policies and regulation Innovative treatments and technologies Improving diagnosis 7 Focus Areas Effective health promotion, disease prevention, preparedness and screening Understanding health, ageing & disease
  • 22. Research and Innovation • European Innovation Partnership on Active and Healthy Ageing • Global Alliance for Chronic Diseases (GACD) – Diabetes (2014) • Joint Programming Initiatives on neurodegenerative diseases (JPND); 'More Years, Better Life's; & Global Research Collaboration for Infectious Disease Preparedness (2014) • ERANETS : Cancer, Systems medicine & rare diseases (2014); Brain-related disorders, antimicrobial resistance, cardiovascular diseases (2015) Support for European and International Initiatives
  • 23. Research and Innovation Strategic Initiatives Innovative Medicines Initiative 2 www.imi.europa.eu European & Developing Countries Clinical Trials Partnership (EDCTP2) www.edctp.org Active and Assisted Living 2 www.aal-europe.eu European Innovation Partnership on Active and Healthy Ageing https://webgate.ec.europa.eu/eipaha
  • 24. Research and Innovation Clinical Trials – Horizon 2020 • Key element of health research supported in Horizon 2020: no innovation without clinical trials! • Specific Programme (legal basis): "translation of research findings into the clinic, in particular through the conduct of clinical trials […] is essential" • 2014/15 calls: Over €300 million of funding earmarked for clinical trials • Emphasis on SMEs and on investigator-driven clinical trials
  • 25. Research and Innovation New EU Clinical Trials Regulation • Responds to criticism of current EU Clinical Trials Directive: • Single submission portal for multinational trials • Joint assessment by member states' competent authorities • Tacit-approval deadlines • Reduced administrative burden (low-risk trials) • Applicable two years after publication (+ transition period)
  • 26. Research and Innovation Innovation Union Commitment n°7 Ensure stronger involvement of SME in future EU R&I programmes * European Council 4 February 2011 Commission is invited to explore the feasibility of a Small Business Innovation Research Scheme Innovation Initiatives
  • 27. Research and Innovation Funding Gap (range: 1-3 M€)
  • 28. Research and Innovation More opportunities for SMEs • Integrated approach - around 20% of the total budget for societal challenges and LEITs to go to SMEs • A new SME instrument will be used across all societal challenges as well as for the LEITs • A dedicated activity for research-intensive SMEs in 'Innovation in SMEs' • 'Access to risk finance' will have a strong SME focus (debt and equity facility) • COSME and H2020 are complementary programmes to generate growth and jobs Image courtesy of Vlado/ FreeDigitalPhotos.net
  • 29. Research and Innovation SME instrument Concept & Feasibility Assessment Innovation R&D activities Commercialisation Phase 2Phase 1 Phase 3 Idea Market • Feasibility of concept • Risk assessment • IP regime • Partner search • Design study • Development, prototype, testing • Miniaturisation/design • Clinical trials • Etc. • Facilitate access to private finance • Support via networking, training, coaching, knowledge sharing, dissemination Lump sum: ~ 50.000 € ~ 6 months Output-based payments: 1 to 5 M€ 12 to 36 months No direct funding Deadlines: 2/3 cut off dates in 2014 for phase 1 & 2

×